Lupin partners with Zentiva to commercialize biosimilar drug

Lupin Limited and Zentiva Group have entered into a license and supply agreement for Lupin's biosimilar Certolizumab Pegol. Under the agreement, Lupin will handle development, manufacturing, and supply, while Zentiva will lead commercialization outside the USA and Canada, primarily in Europe and CIS markets. Lupin will retain commercialization rights for the USA and Canada. Lupin will receive an initial payment of USD 10 million and is eligible for up to USD 50 million in regulatory and development milestone payments. Profits from the defined markets will be shared between the two companies. The collaboration aims to provide more accessible and affordable options for patients requiring Certolizumab Pegol, which is used to treat conditions such as rheumatoid arthritis and Crohn's disease.